Remedium Bio
Remedium Bio is a biotechnology company focused on developing treatments for large unmet clinical needs using a revolutionary gene therapy platform, Prometheus™, which enables safe, effective, and durable delivery of therapeutic genes with simple post-treatment dose adjustment. Their pipeline includes disease-modifying treatments with high efficacy in endocrinology, immunology, neurology, and musculoskeletal diseases, aiming to cure diseases by matching treatment modalities with specific disease pathophysiology.
Industries
Nr. of Employees
small (1-50)
Remedium Bio
15 Necco St, Floor 4, Boston, MA 02210
Products
Single-injection adjustable-dose gene therapy candidate for obesity and type 2 diabetes
Gene therapy approach designed to replace or augment subcutaneously administered protein treatments with a single, adjustable-dose subcutaneous injection intended to produce durable control of metabolic endpoints.
Gene therapy candidate for ischemic stroke
Therapeutic gene constructs intended to provide neuroprotection and support recovery after ischemic stroke, designed to broaden safety margins relative to hemorrhage risk.
Single-injection FGF18 gene therapy candidate for osteoarthritis
A gene therapy approach delivering FGF18 to promote cartilage anabolism and potentially reverse cartilage loss as a single-injection alternative to frequent intraarticular protein injections.
Single-injection adjustable-dose gene therapy candidate for obesity and type 2 diabetes
Gene therapy approach designed to replace or augment subcutaneously administered protein treatments with a single, adjustable-dose subcutaneous injection intended to produce durable control of metabolic endpoints.
Gene therapy candidate for ischemic stroke
Therapeutic gene constructs intended to provide neuroprotection and support recovery after ischemic stroke, designed to broaden safety margins relative to hemorrhage risk.
Single-injection FGF18 gene therapy candidate for osteoarthritis
A gene therapy approach delivering FGF18 to promote cartilage anabolism and potentially reverse cartilage loss as a single-injection alternative to frequent intraarticular protein injections.
Services
End-to-end preclinical development using a modular engineering approach: gene construct design, vector selection, formulation, in vivo efficacy testing, and preparation for clinical translation.
Design and optimization of lipid nanoparticle and polymeric formulations for nucleic acid delivery including intracellular delivery strategies for RNA and DNA cargos.
Execution and management of animal model studies to evaluate therapeutic candidates in disease-relevant models such as mechanically induced osteoarthritis and transient ischemia stroke models.
End-to-end preclinical development using a modular engineering approach: gene construct design, vector selection, formulation, in vivo efficacy testing, and preparation for clinical translation.
Design and optimization of lipid nanoparticle and polymeric formulations for nucleic acid delivery including intracellular delivery strategies for RNA and DNA cargos.
Execution and management of animal model studies to evaluate therapeutic candidates in disease-relevant models such as mechanically induced osteoarthritis and transient ischemia stroke models.
Expertise Areas
- Adjustable-dose gene therapy development
- AAV vector development
- Lipid nanoparticle formulation and non-viral delivery
- Gene construct and promoter engineering
Key Technologies
- Adeno-associated viral vectors (AAV)
- Lipid nanoparticle (LNP) delivery
- Polymeric nanoparticle delivery
- Adjustable-dose gene delivery systems
News & Updates
A gene therapy system that enables adjustable dosing for therapeutic genes, published in Gene on April 23, 2024.
A study demonstrating the efficacy of a single-injection gene therapy for osteoarthritis, published in Current Gene Therapy on January 30, 2024.
A neuroscience manuscript comparing treatments in a stroke model, published in Restorative Neurology and Neuroscience on February 15, 2024.
Research on AAV-delivered FGF18 gene therapy for cartilage growth, published in Cartilage on March 6, 2023.
Poster presentation at the ASBMR conference in 2022 on FGF18 gene therapy for osteoarthritis.
Presentation at the Orthopaedic Research Society in 2023 on FGF18 gene therapy.
A gene therapy system that enables adjustable dosing for therapeutic genes, published in Gene on April 23, 2024.
A study demonstrating the efficacy of a single-injection gene therapy for osteoarthritis, published in Current Gene Therapy on January 30, 2024.
A neuroscience manuscript comparing treatments in a stroke model, published in Restorative Neurology and Neuroscience on February 15, 2024.
Research on AAV-delivered FGF18 gene therapy for cartilage growth, published in Cartilage on March 6, 2023.
Poster presentation at the ASBMR conference in 2022 on FGF18 gene therapy for osteoarthritis.
Presentation at the Orthopaedic Research Society in 2023 on FGF18 gene therapy.